With increased use of transcatheter aortic valve implantation (TAVI) in treatment of aortic stenosis, it is important to evaluate real life data trends in outcomes. This nationwide register-based study aims to present an outlook on temporal trends in characteristics and outcomes including mortality.First-time consecutive Danish TAVI patients from 2010-2019 were included in this study.Chi square and Kruskal-Wallis tests were performed to assess differences in characteristics over time and Cochrane-Armitage trend tests were used to examine changes in complications and mortality.Between 2010-2019, 4,847 patients (54.6% men, median age 82 (Q1-Q3: 77 to 85)) underwent first-time TAVI. Statistically significant decrease over time was observed for pre-procedural hypertension, ischemic heart disease and heart failure (HF), while preexisting chronic obstructive lung disease and pre-procedural pacemaker (PM) remained stable.We observed a significant decrease in 30- and 90-day post operative PM implantation from 2011 to 2017 with 15.1% and 15.9% in 2011 and 8.6% and 8.9% in 2017, respectively.Incidence of HF for 30- and 90-day significantly decreased from 19.3% and 20.3% to 8.5% and 9.1%.We observed significant changes for 30-day atrial fibrillation (AF) while the changes over time for 90-day AF and 30- and 90-day stroke/transient ischemic attack (TIA) remained insignificant.All-cause mortality within 30- and 90-days significantly decreased over time from 6.7% and 9.2% in 2011 to 1.5% and 2.7% in 2019 and 2016.In conclusion this national study provides general insight on trends in complications and mortality of TAVI, demonstrating significant reductions over time.